Global Atopic Dermatitis Treatment Market Size study, by Product (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Biologic Therapy, PDE-4 Inhibitor, Antibiotics, Antihistamines, Emollients) by Indication (Topical, Oral, Injectable) by end use

Global Atopic Dermatitis Treatment Market Size study, by Product (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Biologic Therapy, PDE-4 Inhibitor, Antibiotics, Antihistamines, Emollients) by Indication (Topical, Oral, Injectable) by end use industries (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores, Mail Order Pharmacies, Dermatology Clinics) and Regional Forecasts 2022-2028

Global Atopic Dermatitis Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Atopic dermatitis (AD) is chronic inflammatory skin condition that usually affects the face (cheeks), neck, arms, and legs. It also usually spreads to the groin areas. Atopic dermatitis (AD) is common worldwide. People of all ages from newborns to adults 65 years of age and older live with this condition. Growing prevalence of dermatological skin disorders and rising Research & Development activities in healthcare industry are key drivers for the growth of Atopic Dermatitis Treatment market. For instance, according to National Eczema Association (NEA)- as of 2020 around 31.6 million people (10.1%) in the U.S. are suffering from some type of eczema. And approximately 9.6 million U.S. children under the age of 18 have AD, and one-third have moderate to severe disease. Furthermore, on January 5th , 2022, Swiss pharmaceutical company specializing in dermatological treatments and skin care products Galderma has acquired ALASTIN Skincare, Inc., a California based pharmaceuticals company and on January 14th , 2022, American biopharmaceutical company AbbVie has got approval from the U.S. Food and Drug Administration (FDA) for its new product RINVOQ for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older. Also, with the increasing disposable income and rising healthcare spending, the adoption & demand for Atopic Dermatitis Treatment is likely to increase the market growth during the forecast period. However, high cost of Atopic Dermatitis Treatment and lack of reimbursement policies impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Atopic Dermatitis Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region across the world in terms of market share owing to increasing prevalence of skin disorders and presence of leading market players in the region. Whereas, Asia-Pacific is anticipated to exhibit highest growth rate over the forecast period 2021-2027. Factors such as growing healthcare infrastructure and increasing prevalence of skin diseases among elder population in the region would create lucrative growth prospects for the Atopic Dermatitis Treatment market across Asia-Pacific region.

Major market player included in this report are:
Sanofi SA Ltd.
Galderma SA Pvt Ltd.
Allergan Plc.
Novartis AG Ltd.
Bristol-Myers Squibb Ltd.
Bayer AG Ltd.
Meda Pharmaceuticals Pvt Ltd.
Astellas Pharma Inc.
Anacor Pharmaceutical Inc.
Regeneron Pharmaceuticals, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Biologic Therapy
PDE-4 Inhibitor
Antibiotics
Antihistamines
Emollients
By Indication:
Topical
Oral
Injectable
By End Use Industries:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
Mail Order Pharmacies
Dermatology Clinics
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019,2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Atopic Dermatitis Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Sanofi SA Ltd.
Galderma SA Pvt Ltd.
Allergan Plc.
Novartis AG Ltd.
Bristol-Myers Squibb Ltd.
Bayer AG Ltd.
Meda Pharmaceuticals Pvt Ltd.
Astellas Pharma Inc.
Anacor Pharmaceutical Inc.
Regeneron Pharmaceuticals, Inc.